165 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B N/A
Article Searches
Gilead to Collaborate with Novo Nordisk for NASH Treatment http://www.zacks.com/stock/news/381020/gilead-to-collaborate-with-novo-nordisk-for-nash-treatment?cid=CS-ZC-FT-381020 Apr 15, 2019 - Gilead Sciences (GILD) will collaborate with Novo Nordisk to develop treatments for liver disease, NASH.
Sangamo Rises on Positive Phase I/II Hemophilia Study Data http://www.zacks.com/stock/news/370133/sangamo-rises-on-positive-phase-i-ii-hemophilia-study-data?cid=CS-ZC-FT-370133 Apr 03, 2019 - Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.
What's in the Cards for Aeterna (AEZS) This Earnings Season? http://www.zacks.com/stock/news/357560/whats-in-the-cards-for-aeterna-aezs-this-earnings-season?cid=CS-ZC-FT-357560 Mar 04, 2019 - Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.
Ophthotech's (OPHT) Q4 Loss Wider, Gene Therapy in Focus http://www.zacks.com/stock/news/357166/ophthotechs-opht-q4-loss-wider-gene-therapy-in-focus?cid=CS-ZC-FT-357166 Feb 27, 2019 - Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates http://www.zacks.com/stock/news/356445/pharma-stock-roundup-mrk-buys-imdz-fda-grants-priority-review-to-some-candidates?cid=CS-ZC-FT-356445 Feb 22, 2019 - Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct http://www.zacks.com/stock/news/355654/novo-nordisk-gets-fda-nod-for-haemophilia-drug-esperoct?cid=CS-ZC-FT-355654 Feb 20, 2019 - Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
2 Healthcare Stocks Ripe for a Takeover https://www.fool.com/investing/2019/02/17/2-healthcare-stocks-ripe-for-a-takeover.aspx?source=iedfolrf0000001 Feb 17, 2019 - Amarin and Aphria could both be bought out soon.
Seattle Genetics' Adcetris Gets EC Nod for Label Expansion http://www.zacks.com/stock/news/354019/seattle-genetics-adcetris-gets-ec-nod-for-label-expansion?cid=CS-ZC-FT-354019 Feb 12, 2019 - Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.
Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth http://www.zacks.com/stock/news/352788/sanofi-sny-q4-earnings-top-genzyme-unit-drives-sales-growth?cid=CS-ZC-FT-352788 Feb 07, 2019 - Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.
Novo Nordisk Is on the Upswing -- for Now https://www.fool.com/investing/2019/02/05/novo-nordisk-is-on-the-upswing-for-now.aspx?source=iedfolrf0000001 Feb 05, 2019 - The full year may be a different story.

Pages: 12345678...17

<<<Page 3>